Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094052
Filing Date
2024-08-08
Accepted
2024-08-08 16:21:48
Documents
80
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sana-20240630.htm   iXBRL 10-Q 2669977
2 EX-10.1 sana-ex10_1.htm EX-10.1 22890
3 EX-10.2 sana-ex10_2.htm EX-10.2 75734
4 EX-31.1 sana-ex31_1.htm EX-31.1 16422
5 EX-31.2 sana-ex31_2.htm EX-31.2 15214
6 EX-32.1 sana-ex32_1.htm EX-32.1 8593
7 EX-32.2 sana-ex32_2.htm EX-32.2 8356
8 GRAPHIC img112679855_0.jpg GRAPHIC 392794
  Complete submission text file 0000950170-24-094052.txt   10706232

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sana-20240630.xsd EX-101.SCH 1330695
82 EXTRACTED XBRL INSTANCE DOCUMENT sana-20240630_htm.xml XML 1678818
Mailing Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102
Business Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102 (206) 701-7914
Sana Biotechnology, Inc. (Filer) CIK: 0001770121 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39941 | Film No.: 241188750
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)